Company news
Recce Pharmaceuticals Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Patient Dosing Underway in Ph 3 Indonesia DFI Trial
September 25, 2025
Preliminary Final Report
August 29, 2025
R327G Highly Effective in Burn Wounds Model
August 12, 2025
Recce Signs Debt Facility with Avenue Capital Group
June 17, 2025
Successful Placement of Entitlement Offer Shortfall
June 3, 2025
China Patent Accepted for RECCE Anti-Infectives
May 26, 2025
Recce Enters into USA Department of Defense R&D Agreement
April 27, 2025
Recce Pharmaceuticals Receives Approval for Additional Phase II Trial of RECCE® 327 Topical Gel for Diabetic Foot Infections
April 23, 2025
Entitlement Offer - Offer Booklet and Access Letter
April 22, 2025
Phase II Clinical Trial Receives Additional Approval for DFI
April 22, 2025
Recce Pharmaceuticals Announces A$5.0 million Placement & Launches A$10.8 million Entitlement Offer to Shareholders
April 10, 2025
Placement and Entitlement Offer to Fund Phase III Trials
April 10, 2025
Key Opinion Leader Presentation
March 2, 2025
Recce Pharmaceuticals Granted Japanese Patent for RECCE® Anti-Infectives
February 27, 2025
Japan Patent Allowance for RECCE Anti-Infectives
February 25, 2025
Recce Pharmaceuticals Reports Positive Data from Phase II Trial of RECCE® 327 Gel in Acute Bacterial Skin and Skin Structure Infections, Supporting Accelerated Commercialization Pathway
February 19, 2025
Positive Phase II Data from Clinical Trial of R327 Gel
February 16, 2025
Trading Halt
February 13, 2025
Pause in Trading
February 13, 2025
Correction to Appendix 4C and Quarterly Activities Report
February 6, 2025
Patient Dosing Complete in Phase II ABSSSI Trial of R327G
January 20, 2025
Regulatory Approval for Registrational Phase 3 R327G Trial
December 8, 2024
Australia Patent Granted for RECCE Anti-Infectives
November 25, 2024
AUD $6.75m R&D Rebate Approved
November 13, 2024
Ethics Approval for Registrational Ph3 R327G Clinical Trial
November 10, 2024
AGM Presentation
November 5, 2024
Phase II ABSSSI Clinical Trial Advances to Final Stages
November 4, 2024
Efficacy Data & Approval to Continue Ph II ABSSSI Trial
October 27, 2024
Ph II ABSSSI Trial Recruitment and Dosing Passes Halfway
October 8, 2024
Notice of Special General Meeting/Proxy Form
October 8, 2024
Recce Pharmaceuticals Announces Successful Completion of Share Purchase Plan
August 6, 2024
Successful Completion of Share Purchase Plan
August 4, 2024
Recce Pharmaceuticals Receives $2 Million Grant from U.S. Department of Defense for RECCE® 327 Gel
July 16, 2024
US Department of Defense Grants US $2m for R327G
July 15, 2024
R327 Efficacy against WHO Priority Pathogen Acinetobacter B
July 8, 2024
Placement & SPP to raise $10 million - Funded to FY26
July 2, 2024
Phase I/II UTI/Urosepsis Rapid Infusion Trial Complete
June 27, 2024
Ethics Approval Broadens to All Topical Infections
June 24, 2024
Further R&D Rebate Approved
June 18, 2024
R327 added to WHO List of Antibacterial Products
June 18, 2024
Cohort Dosing Complete Ph I/II UTI/Urosepsis Clinical Trial
June 10, 2024
Ph I/II UTI/Urosepsis Trial Dosing Commenced in Next Cohort
May 15, 2024
MCRI Pilot Study- Positive Efficacy Data for Lung Infections
May 9, 2024
China Patent Granted for RECCE Anti-Infectives
May 6, 2024
Safety Committee Approves High Dose of 4,000mg
April 26, 2024
Recce Completes 5,000 R327 Doses Per Week under GMP
April 16, 2024
Recce Pharmaceuticals - Business Update
April 7, 2024
Patent Granted in Israel for RECCE Anti-Infectives
April 2, 2024
Next Cohort Dosing Ph I/II UTI/Urosepsis Clinical Trial
March 12, 2024
Recce Receives AUD $11.17m R&D Advance
March 7, 2024
Decks
The 5 newest of 45 decks. Every deck is listed under its year.
- Shareholder Meeting (November 2026)
Shareholder meeting · 19 slides · Nov 6, 2026
- Investor Presentation (November 2026)
Investor deck · 45 slides · November 2026
- Investor Presentation (October 2026)
Investor deck · 42 slides · October 2026
- Shareholder Meeting (September 2026)
Shareholder meeting · 10 slides · Sep 2, 2026
- Investor Presentation (September 2026)
Investor deck · 42 slides · September 2026